Ribociclib
- Generic Name
- Ribociclib
- Brand Names
- Kisqali 200 Mg Daily Dose Carton, Kisqali Femara Co-pack, Kisqali
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N8O
- CAS Number
- 1211441-98-3
- Unique Ingredient Identifier
- TK8ERE8P56
- Background
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring tha...
- Indication
用于联合芳香酶抑制剂或氟维司群治疗激素受体(HR)阳性、人表皮生长因子受体2(HER2)阴性的晚期或转移性乳腺癌成人患者。
- Associated Conditions
- Advanced Breast Cancer, Metastatic Breast Cancer
- Associated Therapies
- -
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
- Conditions
- Interventions
- Drug: AdavosertibDrug: RibociclibDrug: OlaparibDrug: VistusertibDrug: NivolumabDrug: EnasidenibDrug: FutibatinibDrug: FadraciclibDrug: CytarabineDrug: TopotecanDrug: EverolimusDrug: CarboplatinDrug: IrinotecanDrug: CyclophosphamideDrug: SelumetinibDrug: LirilumabDrug: CeralasertibDrug: CapmatinibDrug: TemozolomideDrug: Dexamethasone
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 460
- Registration Number
- NCT02813135
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
🇳🇱Erasmus MC, Sophia Children's Hospital, Rotterdam, Netherlands
Next Generation Personalized Neuroblastoma Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Yael P Mosse
- Target Recruit Count
- 66
- Registration Number
- NCT02780128
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
- Conditions
- Interventions
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 104
- Registration Number
- NCT02732119
- Locations
- 🇺🇸
Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States
🇺🇸St. Luke's Cancer Institute Regulatory, Kansas City, Missouri, United States
🇺🇸Research Medical Center HCA Midwest Division, Kansas City, Missouri, United States
Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Qamar Khan
- Target Recruit Count
- 121
- Registration Number
- NCT02712723
- Locations
- 🇺🇸
University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
🇺🇸University of Kansas Cancer Center - West, Kansas City, Kansas, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 95
- Registration Number
- NCT02703571
- Locations
- 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Dana Farber Cancer Center, Boston, Massachusetts, United States
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
- First Posted Date
- 2016-01-18
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 40
- Registration Number
- NCT02657928
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
- Conditions
- Interventions
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT02657343
- Locations
- 🇺🇸
Massacusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 20
- Registration Number
- NCT02608216
- Locations
- 🇺🇸
University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2020-11-05
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 11
- Registration Number
- NCT02607124
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.